meta
|
evidence
oncology
Living systematic review and meta-analysis
castration-resistant prostate cancer (CRPC)
metastatic (mCRPC) - 1st line (L1)
3
metastatic (mCRPC) - 2nd line (L2)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
nivolumab based treatment
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab plus enzalutamide
Immune checkpoint association
durvalumab plus tremelimumab
poly ADP-ribose polymerase (PARP) inhibitor
olaparib
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
vs endocrine therapy
vs androgen deprivation therapy (ADT)
vs enzalutamide
vs placebo plus enzalutamide
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs anti-PD-(L)1
vs durvalumab based treatment
vs durvalumab alone
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network